Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
暂无分享,去创建一个
[1] A. Tsao,et al. Use of Immune Checkpoint Inhibitors in Mesothelioma , 2019, Current Treatment Options in Oncology.
[2] J. Szustakowski,et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2019, Cancer cell.
[3] S. Lantuejoul,et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet. Oncology.
[4] E. Thunnissen,et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[6] A. Wozniak,et al. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive‐Stage Small Cell Lung Cancer (SCLC) , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Jacob Silterra,et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.
[8] J. Nemunaitis,et al. Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC). , 2018 .
[9] W. Miller,et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. , 2018 .
[10] A. D’Incecco,et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. , 2018, The Lancet. Respiratory medicine.
[11] J. Nemunaitis,et al. Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC). , 2018 .
[12] S. Albelda,et al. Novel therapies for malignant pleural mesothelioma. , 2018, The Lancet. Oncology.
[13] G. Giaccone,et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. , 2018, The Lancet. Oncology.
[14] J. Shrager,et al. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] K. Nackaerts,et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.
[16] J. Aerts,et al. Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.
[17] I. Wistuba,et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms , 2017, Modern Pathology.
[18] Haiyi Jiang,et al. A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian. , 2017 .
[19] J. Schlom,et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. , 2017, The Lancet. Oncology.
[20] A. Santoro,et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.
[21] D. Jäger,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[22] Pingli Wang,et al. Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. , 2016, Journal of thoracic disease.
[23] R. West,et al. Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] P. Meltzer,et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.
[25] G. Ceresoli,et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. , 2012, Lung cancer.
[26] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[27] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[28] S. Gettinger,et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.
[29] T. Lynch,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.